INTRODUCTION: Depression is the main psychiatric comorbidity in epilepsy with an estimated prevalence between 20% and 55% and one of the main determinants of quality of life. The aim of this study was to investigate the effect of lacosamide (LCM) on mood and anxiety symptoms in patients with focal onset seizures (FOS). The secondary objective was to evaluate if the potential modifications in variables were related to seizure control or to the intrinsic effect of LCM. MATERIAL AND METHODS: We performed a prospective multicenter study in 8 tertiary epilepsy centers in adults with FOS in which LCM was initiated as add-on therapy. Patients' mood and quality of life were evaluated through questionnaires and scales such as the Beck Depression Inventory-II (BDI-II), the State-Trait Anxiety Inventory (STAI-S/T), the Hospital Anxiety and Depression Scale (HADS), and the Quality of Life in Epilepsy-10 (QOLIE-10). Initiation of psychotropic medication was not allowed during the observation period. Patients with diagnosis of major depression or bipolar disorder were excluded. Evaluations were scheduled before LCM treatment, at 3 and 6 months. RESULTS: Forty-nine patients were included (51% female) with an average age of 39.5 years (range 18-65). At the start of treatment with LCM, 65.3% of the patients were on treatment with one antiepileptic drug (AED). Based on BDI-II, 38.8% of patients had depressive symptoms and 46.9% according to HADS Depression (HADS-D), 63.3% of patients presented pathological levels of anxiety (STAI-S/T), and 44.9% according to HADS Anxiety (HADS-A). Quality of Life in Epilepsy-10 showed that 57.1% of patients had a relevant reduction in their quality of life. After LCM, the score on the BDI-II depression scale decreased significantly (p < 0.001). Based on the STAI and HADS anxiety scales, patients who had a pathological anxiety at baseline, significantly improved. The QOLIE-10 improved significantly over the observation period (p < 0.001). At 6 months, 28.3% of patients were seizure-free (67.4% were responders). The improvements on depression and anxiety scores were not statistically related to seizure control. CONCLUSION: Lacosamide seems to have a positive effect on depressive and anxiety symptoms. Although the efficacy of LCM in seizure control was demonstrated, the antidepressant and anxiolytic effect on mood and anxiety seems to be an independent factor.
Commentary
Anxiety (12-22%; 1), depression (22-55%; 2) and behavioral changes, like the ones seen in attention deficit with hyperactivity (ADHD; 27%; 3), are common in people with epilepsy. They are considered risk factors and co-existing manifestation of the disease (4) . Symptoms of depression and anxiety often precede the onset of seizures and the diagnosis of epilepsy (4, 5) ; vice versa, the diagnosis of epilepsy is often followed by the development of active psychopathology. The consequence of this constellation of seizures and psychiatric symptoms is often worsening quality of life that requires a comprehensive therapeutic approach.
If we think of the relation between mood, behavior, and epilepsy as a spectrum of a common neurobiological mechanism, it seems intuitive that the treatment for some of these symptoms would have an effect on the others. It would make sense for anti-seizure medications to also affect other manifestations of the disease in positive ways. However, unlike we are with tracking seizures, we are yet not very skilled in actively looking for these symptoms or tracking their evolution over time.
The first step to addressing the problem is to obtain some form of psychological baseline and an assessment on depression, anxiety, and suicidality in the clinic. Self-administered screening tools are widely available, easy to apply, and free for healthcare providers to use (6) . These tools take a short time to score and may inform anti-seizure medication choice. They also allow for proactive followup, signaling the development or worsening of psychiatric symptoms and leading to timely intervention.
It may not be intuitive for many patients to report mood, emotional, or behavioral changes to their neurologists unless the provider takes an active role inquiring about them. In addition, patients may not think of reporting psychiatric symptoms as side effects of medications. They need to be educated about this possibility and given an action plan in case these symptoms arise or worsen. Keep in mind that prevention is the only possible intervention to combat deadly complications such as suicide.
Psychiatric side effects of anti-seizure medications are common (17.2%) and not always positive, even when seizures are controlled (7). They are a frequent reason for medication discontinuation. Psychiatric and behavioral side effects of levetiracetam are reported in up to 22% of patients (7), which is significantly higher than other anti-seizure medications. Carbamazepine, valproic acid, gabapentin, and lamotrigine have been associated with beneficial psychiatric and behavioral effects.
Guilfoyle et al. reported a step-based proactive approach for screening children and adolescents for comorbid behavioral and mood disorders, addressing the effects of AEDs on mood and depression. As reported in adults, the existence of premorbid psychiatric conditions seems to be the best predictor for the development of mood and behavioral side effects when medications are started. Children expressed more behavioral symptoms (irritability and agitation), while adolescents showed more mood-related symptoms as side effects of AEDs. This study highlights the need for establishing a psychological baseline and followup for children and adolescents with epilepsy. The baseline is instrumental at the time of choosing AEDs but also for evaluating side effects and detecting psychopathology in time to make treatment adjustments. Interestingly, contrary to the expected, Guilfoyle and colleagues did not find significant difference in children's behavioral side effects among anti-seizure medications popularly thought to have contrasting psychotropic side effects, such as valproic acid, levetiracetam, and carbamazepine.
Rocamora et al. prospectively evaluated the evolution of psychiatric symptoms in patients with focal epilepsy treated with lacosamide as an adjuvant therapy and tried to isolate the effect of lacosamide on mood and quality of life, independent of seizure control. They found significant improvement in depression, anxiety, and quality of life related to the medication. Prior studies (8, 9) have showed results in a similar direction, thereby strengthening the evidence in support of a positive psychotropic effect of lacosamide.
Knowing that both the underlying condition as well as our medication choice may have the ability to worsen or improve our patients' psychopathology presents a challenge and an opportunity. The challenge is to proactively identify our patients at risk and start treatment when needed; the opportunity is to learn to use medications wisely to the maximum benefit for our patients while avoiding polypharmacy and medication interactions. We need to ensure that our interventions are not making the situation worse, no matter how well we achieve seizure control. We need to make sure our remedy is not worse than the disease.
Having effective treatment options that also have psychotropic benefits is a real advantage in the clinic-more so if satisfactory results are also achieved in seizure control.
Five ideas come to mind in putting this knowledge to use in the clinic scenario:
1. Psychiatric co-morbidities of epilepsy and anti-seizure medication psychiatric side effects may co-exist. Medication changes may be needed to address any active concerns.
greater AED behavioral side effects (M = 25.08 ± 26.36) compared to adolescents (M = 12.36 ± 17.73), regardless of AED. Valproic acid demonstrated significantly greater behavioral side effects compared to all other AEDs, with the exception of levetiracetam. Higher hyperactivity/impulsivity at baseline significantly predicted higher AED behavioral side effects 1 month after AED initiation in both age groups. SIGNIFICANCE: Younger children seem to be more prone to experience behavioral side effects, and these are likely to be higher if youths with epilepsy have baseline hyperactivity/impulsivity. Baseline psychological screening, specifically hyperactivity, can be used as a precision medicine tool for AED selection.
2. The only way to evaluate a psychotropic result following any intervention is with proactive, appropriate, directed, and standardized followup.
3. Patients need to be educated about both possible psychiatric side effects and possible side benefits of anti-seizure medications.
4. Mood and behavioral changes may happen when starting a new medication and when adjusting doses or discontinuing medications as they might have been exerting a positive psychotropic side effect.
5. Be aware of vulnerable populations-such as children, adolescents, and the elderly-who may have atypical presentations of depression.
by Adriana Bermeo-Ovalle, MD
